MK-677 vs Sermorelin

Overview

MK-677 (ibutamoren) is an oral, non-peptide ghrelin mimetic that was investigated but never approved. Sermorelin is a GHRH analog that was previously FDA-approved (Geref) but discontinued. Both are now available through compounding pharmacies or as research chemicals.

Important distinction: Sermorelin was once an approved drug (now discontinued); MK-677 was never approved. Neither is currently available as an FDA-approved product.

Key Facts

Aspect	MK-677 (Ibutamoren)	Sermorelin
Class	Non-peptide ghrelin mimetic	GHRH analog (peptide)
Administration	Oral	Subcutaneous injection
FDA Status	Never approved	Previously approved (discontinued)
Current Availability	Research chemical	Compounding pharmacies
Mechanism	Ghrelin receptor agonist	GHRH receptor agonist

Mechanism Comparison

Aspect	MK-677	Sermorelin
Target Receptor	Ghrelin receptor (GHS-R1a)	GHRH receptor
Pathway	Mimics ghrelin	Mimics natural GHRH
Oral Bioavailability	Yes	No (injectable only)
Half-life	~4-6 hours	~10-20 minutes
Duration of Effect	Extended (24hr IGF-1 elevation)	Short (requires multiple daily doses)

How They Work

MK-677:

• Non-peptide compound that mimics ghrelin
• Binds ghrelin receptors in hypothalamus and pituitary
• Stimulates GH release and increases appetite
• Single daily dose maintains elevated IGF-1
• Does not require injection

Sermorelin:

• Synthetic analog of natural GHRH (first 29 amino acids)
• Binds GHRH receptors on pituitary
• Stimulates natural GH synthesis and release
• Short half-life requires multiple daily injections
• Works through physiologic GHRH pathway

Evidence Quality

MK-677 Research

Trial Type	Status	Key Findings
Phase 2 (various)	Completed	Increased GH/IGF-1 levels
Elderly/muscle studies	Completed	Some function improvements
Hip fracture	Completed	Did not meet primary endpoints
FDA Approval	Not pursued	Development discontinued

Research summary:

• Multiple Phase 2 trials conducted
• Consistently increased GH and IGF-1
• Failed to show clinical benefit in target populations
• Glucose/insulin effects contributed to discontinuation

Sermorelin Research

Trial Type	Status	Key Findings
Pediatric GH deficiency	Completed	Approved 1997 (Geref)
Adult studies	Limited	Some data available
Market withdrawal	2008	Manufacturing/commercial reasons
Current use	Off-label	Compounding pharmacies

Historical context:

• Was FDA-approved for pediatric GH deficiency testing
• Market withdrawal was not due to safety concerns
• Limited data for adult anti-aging uses
• Now available through compounding

Evidence Strength Comparison

Factor	MK-677	Sermorelin
Peer-reviewed studies	More extensive	Moderate
FDA review	Clinical hold history	Previously approved
Human trial data	Yes (Phase 2)	Yes
Long-term safety	Concerns identified	Limited data
Overall quality	Low-Moderate	Moderate

Efficacy Comparison

GH/IGF-1 Effects

Parameter	MK-677	Sermorelin
GH increase	Significant	Moderate
IGF-1 increase	Sustained 24hr	Pulsatile, variable
Magnitude	40-60% IGF-1 increase	Variable, generally lower
Consistency	More consistent	Depends on pituitary function

Practical Outcomes

Outcome	MK-677	Sermorelin
Muscle mass	Some evidence	Limited evidence
Fat reduction	Limited evidence	Limited evidence
Sleep improvement	Reported (REM)	Reported
Clinical efficacy	Not established	Not established for anti-aging

Side Effects

MK-677 (From Clinical Trials)

Side Effect	Incidence	Concern Level
Increased appetite	Very common	Expected (ghrelin effect)
Water retention	Common	Moderate
Increased blood glucose	Common	Significant
Insulin resistance	Documented	Significant
Lethargy/fatigue	Common	Moderate
Joint pain	Reported	Moderate

Major concern: Glucose dysregulation is a documented effect that contributed to discontinuation of development.

Sermorelin (Limited Data)

Side Effect	Reported	Notes
Injection site reactions	Common	Pain, redness, swelling
Facial flushing	Occasional	Transient
Headache	Occasional	Usually mild
Dizziness	Rare	—

Key difference: Sermorelin has a cleaner metabolic profile - no significant effect on glucose or appetite.

Safety Profile Comparison

Concern	MK-677	Sermorelin
Glucose metabolism	Worsens	No significant effect
Insulin sensitivity	Decreases	No significant effect
Appetite stimulation	Significant	Minimal
Water retention	More pronounced	Mild
Long-term safety	Concerns exist	Less characterized

Practical Comparison

Factor	MK-677	Sermorelin
Route	Oral (capsule/liquid)	Injection (subcutaneous)
Convenience	Higher (no injection)	Lower (injections required)
Reconstitution	Not needed	Required
Storage	Room temperature (usually)	Refrigerated

Availability Comparison

Factor	MK-677	Sermorelin
Legal status	Research chemical	Compounded medication
Prescription available	No	Yes (compounding)
Quality assurance	None	Compounding pharmacy standards
Medical oversight	Typically none	Available with prescription
Cost	Variable (~$50-150/month)	Variable (~$150-400/month)

Regulatory Considerations

MK-677

• Never FDA-approved
• Sold as research chemical (“not for human consumption”)
• No pharmaceutical-grade products
• Quality and purity uncertain

Sermorelin

• Previously FDA-approved (Geref)
• Withdrawn for commercial/manufacturing reasons
• Available through compounding pharmacies
• Requires prescription from licensed provider
• Subject to state compounding regulations

Who Might Consider Each

MK-677 Often Chosen By:

• Those avoiding injections
• Those prioritizing convenience
• Research/experimental contexts
• Concerns: No medical oversight, quality unknown, metabolic risks

Sermorelin Often Chosen By:

• Those wanting medical supervision
• Anti-aging clinic patients
• Those with pre-diabetes/metabolic concerns (better profile)
• Advantage: Compounded product with some quality standards

Combination Use

In some anti-aging protocols, GHRH analogs (like sermorelin) are combined with GHRPs or ghrelin mimetics for synergistic GH release:

Combination	Rationale
Sermorelin + Ipamorelin	GHRH + GHRP pathways
Sermorelin + GHRP-6	Different receptors, synergy
MK-677 alone	Already produces robust response

Note: Combination protocols lack clinical validation.

Summary

Factor	MK-677	Sermorelin
Mechanism	Ghrelin receptor	GHRH receptor
Administration	Oral	Injection
FDA status	Never approved	Previously approved (discontinued)
Current availability	Research chemical	Compounding pharmacies
Quality assurance	None	Some (compounding standards)
Metabolic effects	Concerns (glucose, insulin)	Cleaner profile
Medical oversight	Typically none	Available
Convenience	Higher	Lower

Key takeaway: MK-677 offers oral convenience but with documented metabolic concerns and no quality assurance. Sermorelin requires injections but has a cleaner metabolic profile and is available through compounding pharmacies with medical supervision. Neither is FDA-approved for anti-aging or body composition uses.

---

This comparison is for educational purposes only. Neither compound is FDA-approved for anti-aging or performance uses. MK-677 is a research chemical. Sermorelin requires a prescription. Consult a healthcare provider before considering any GH secretagogue.